ArticleMedicine2026
Long-term quality of life and its determinants in gynecologic cancer survivors after pelvic exenteration: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate long-term quality of life (QoL) in gynecologic cancer survivors after pelvic exenteration (PE) and to identify clinical factors associated with impaired QoL. This retrospective cohort study included patients with gynecologic cancer who underwent PE at a tertiary referral center between January 2015 and December 2022. Demographic, clinical, surgical, and treatment-related variables were collected from institutional records. Univariate analyses were performed to identify factors associated with global QoL scores, and variables with P < .10 were entered into a multivariable linear regression model. A total of 58 patients were included, with a median age of 56 years and a median follow-up of 38 months. The mean global QoL score was 62.4 ± 14.7. Patients with permanent stoma formation reported significantly lower global QoL than those without stoma (57.1 vs 72.3, P < .001). In multivariable analysis, permanent stoma formation (B = -12.73, 95% confidence interval [CI] = -19.62 to -5.85; standardized β = -0.41; P < .001), severe postoperative complications (B = -10.65, 95% CI = -17.75 to -3.55; β = -0.32; P = .004), tumor recurrence during follow-up (B = -8.71, 95% CI = -15.05 to -2.37; β = -0.29; P = .008), and postoperative radiotherapy (B = -6.14, 95% CI = -11.69 to -0.58; β = -0.21; P = .031) were independently associated with lower global QoL. The model had an adjusted R2 of 0.42 (F[4,53] = 7.99, P < .001). In a sensitivity analysis additionally adjusting for primary tumor site, primary versus recurrent disease at PE, and time from surgery to QoL assessment, the direction of the main associations remained unchanged, although the effect of postoperative radiotherapy was attenuated (P = .061). Gynecologic cancer survivors undergoing PE may achieve moderate long-term QoL, although persistent symptom burden remains common. Permanent stoma formation, severe postoperative complications, tumor recurrence, and postoperative radiotherapy were associated with poorer QoL. These findings support careful patient counseling, optimized perioperative management, and multidisciplinary survivorship care after PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.